Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616000908437
Ethics application status
Approved
Date submitted
23/05/2016
Date registered
8/07/2016
Date last updated
27/08/2024
Date data sharing statement initially provided
18/02/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
The Cancer Molecular Screening and Therapeutics (MoST) Program-Screening
Scientific title
The Cancer Molecular Screening and Therapeutics (MoST) Program - A framework protocol for multiple, parallel, signal-seeking clinical studies of novel molecularly targeted therapies for patients with advanced cancer and unmet clinical need.
Secondary ID [1] 289299 0
Nil known
Universal Trial Number (UTN)
U1111-1182-6652
Trial acronym
MoST
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cancer 298691 0
Condition category
Condition code
Cancer 298746 298746 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Molecular screening for actionable biomarkers to be used to guide therapy.
Hospital archival tumour tissue will be collected for molecular screening after participant consent and assessment of suitability for the study.

The Garvan Institute of Medical Research will coordinate the molecular screening from archival tumour tissue. The core assays will be based on a genomic sequencing panel to cover a broad range of potentially actionable or biologically important cancer genes, with subsequent bioinformatics analysis. Patient tumour samples will also be assessed for biomarkers using relevant assays such as immunohistochemistry.

Molecular screening results will be reviewed by a Molecular Tumour Board. Options for treatment as a result of the screening will fall into 3 categories:

1. A MoST program clinical trial
2.A clinical trial outside of the program
3. Other treatments outside of the MoST program at the discretion of the participant's clinician

All participants, including those with no ‘actionable’ biomarkers, will be informed of the results of the screening of their tumour tissue through their clinician.
Intervention code [1] 294686 0
Early detection / Screening
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 298228 0
To evaluate a mechanism for screening patients for actionable biomarkers used to guide therapy by measuring a combination of factors (identified individually as secondary outcomes)
Timepoint [1] 298228 0
For the duration of the study. estimated at 4 years. The outcomes will be reviewed regularly and at least annually.
Secondary outcome [1] 325496 0
1. the number of actionable molecular biomarkers identified in screened patients;
Timepoint [1] 325496 0
For the duration of the study. Estimated at 4 years
Secondary outcome [2] 325497 0
2. the number of patients whose therapy is altered on the basis of molecular screening and type of intervention (existing therapy/other trial/MoST substudy);
Timepoint [2] 325497 0
For the duration of the study. Estimated at 4 years
Secondary outcome [3] 325498 0
3. the number of patients enrolled into screening over defined periods;
Timepoint [3] 325498 0
For the duration of the study. Estimated at 4 years
Secondary outcome [4] 325499 0
4. the number of patients eligible for enrolment onto one or more MoST substudy and the number of patients registered onto each substudy;
Timepoint [4] 325499 0
For the duration of the study. Estimated at 4 years
Secondary outcome [5] 325500 0
5. the time taken from patient consenting to communication of screening results to patient;
Timepoint [5] 325500 0
For the duration of the study. Estimated at 4 years
Secondary outcome [6] 325501 0
6. the time taken from identification of an actionable mutation by the MTB (defined as the date of the MTB report) to registration of patient into substudy;
Timepoint [6] 325501 0
For the duration of the study. Estimated at 4 years
Secondary outcome [7] 325502 0
7. a qualitative and quantitative analysis of the molecular screening assays, including sequencing failure rate, costs per genotype screened;
Timepoint [7] 325502 0
For the duration of the study. Estimated at 4 years
Secondary outcome [8] 325503 0
8. the overall survival of patients whose treatment was altered as a result of molecular profiling (either on MoST, via another trial, or other mechanism) compared to those who received standard therapy;
Timepoint [8] 325503 0
For the duration of the study. Estimated at 4 years
Secondary outcome [9] 325504 0
9. a qualitative analysis of patient expectations of the genomic screening and observed clinical outcomes (as reported by questionnaire specifically designed for this study).
Timepoint [9] 325504 0
For the duration of the study. Estimated at 4 years
Secondary outcome [10] 325505 0
To evaluate the composite outcomes of feasibility, efficiency and utility of an overarching framework protocol for multiple, parallel signal-seeking clinical substudies by measuring:

the time from concept proposal to opening of MoST substudy;
the time from ethics approval of MoST program to opening of the first substudy
the time from ethics approval of the addenda to opening of substudies
the number of MoST substudies which yield a positive signal of activity and proceed to formal phase II testing
the number of biomarkers of response identified
timelines to meet key milestones including time taken from: concept proposal to submission of substudy addendum as amendment ethics; amendment submission to ethics approval; ethics approval to substudy opening; substudy opening to completion of enrolment; completion of enrolment to study closure; study closure to reporting of results.
Timepoint [10] 325505 0
For the duration of the study. Estimated at 4 years
Secondary outcome [11] 374013 0
Progression free survival (PFS)
Timepoint [11] 374013 0
For the duration of the study. PFS is defined as the interval from the date of registration to the date of first evidence of disease progression or death from any cause, whichever occurs first.
Secondary outcome [12] 374014 0
Progression free survival (PFS) at 6 months
Timepoint [12] 374014 0
PFS is defined at 6 months and it is the interval from date of registration to the date of first evidence of disease progression or death from any cause, whichever occurs first.

Eligibility
Key inclusion criteria
Inclusion Criteria - Molecular Screening
1. Male or female patients, aged 18 years and older, with pathologically confirmed advanced and/or metastatic solid cancer of any histologic type or an earlier diagnosis of a poor prognosis cancer;
2. Sufficient and accessible tissue for molecular screening;
3. Patients receiving their last line of standard treatment or who have received and failed all standard anticancer therapy (where standard therapy exists) or have documented unsuitability for any further standard anticancer therapy. Poor prognosis cancers or cancers with low expected response rate to standard treatment (in the opinion of the investigator and based on available evidence) may be screened on an earlier line of treatment.
a. Failure is defined as either progression of disease (clinical or radiological) or intolerance to standard therapy resulting in the discontinuation of the therapy.
b. Documented unsuitability for further standard therapy includes known hypersensitivity, organ dysfunction or other patient factors that would make therapy unsuitable in the judgement of the responsible investigator;
4. ECOG performance status 0, 1 or 2;
5. Willing and potentially able to comply with study requirements, including treatment, timing and/or nature of required assessments; It is the intention to screen patients who are in principle wishing to take part in a MoST substudy if they are found to have an appropriate tumour biomarker and are still eligible for enrolment at the time of the treatment phase;
6. Signed, written informed consent to participation in the molecular screening

Inclusion Criteria - Treatment sub-study
To be eligible for treatment in a substudy, patients must continue to meet all of the inclusion criteria and none of the exclusion criteria specified for entry into molecular screening at the time of registration to a treatment substudy. In addition, they must meet all the inclusion criteria and none of the exclusion criteria specified for entry into a treatment substudy.

1. Confirmation of molecular eligibility by the molecular tumour board;
2. Received and failed all standard anticancer therapy or have documented unsuitability for any further standard therapy, if standard therapy exists;
3. Clinical or radiological progression on or following last anticancer therapy;
4. Adequate organ system function as assessed per the protocol
5. Meet any additional inclusion criteria specified in the relevant substudy addendum;
6. Signed, written informed consent to participation in the specific treatment substudy.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria - Molecular Screening
1. Suitable for standard therapy or accepted standard care, if the patient has not been previously treated;
2. Specific comorbidities or conditions (e.g. psychiatric) or concomitant medications which may contraindicate participation and/or interact with the investigational product(s);
3. Other co-morbidities or conditions that may compromise assessment of key outcomes or in the opinion of the clinician, limit the ability of the patient to comply with the protocol;
4. For non central nervous system (CNS) cancers, patients with symptomatic CNS involvement of his/her cancer. Subjects with stable neurological function ,on stable doses of steroids/anti-epileptics over 4 weeks, and with no evidence of CNS progression within 12 weeks prior to study entry are eligible;
5. History of another malignancy within 2 years prior to registration unless adequately treated and determined free of progressive and metastatic disease for at least 6 months. Patients with a past history of adequately treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or superficial transitional cell carcinoma of the bladder are eligible;
6. Pregnancy, lactation, or inadequate contraception. Women must be post-menopausal, infertile, or use a reliable means of contraception. Women of childbearing potential must have a negative pregnancy test done within 7 days prior to registration. Men must have been surgically sterilised or use a barrier method of contraception (double barrier, if required).

Exclusion criteria - Treatment Sub-study

Exclusion criteria will include those relevant for screening but also include:
1. Contraindications to investigational product, as listed in the substudy addendum and outlined in the Investigator Brochure appended to each substudy module;
2. Known history of hypersensitivity to active or inactive components of investigational product;
3. Previous treatment with the same agent or same class of agent;
4. Treatment with any of the following anti-cancer therapies prior to the first dose of study treatment:
o Radiation therapy, surgery or tumour embolization within 14 days prior to the first dose of study treatment. Palliative radiotherapy (for analgesia) is acceptable only if the irradiated field does not include target lesions;
o Immunotherapy within 28 days prior to the first dose of study treatment;
o Chemotherapy, biologic therapy, or hormonal therapy within 14 days or 5 half-lives of a drug prior to the first dose of study treatment or until recovery from previous therapy (whichever is longer);
5. Administration of any investigational treatment within 30 days or 5 half-lives (whichever is longer) prior to receiving the first dose of study treatment;
6. Any additional exclusion criteria specified in the relevant substudy addendum.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
NA
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
NA
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
This framework protocol provides a structure to screen patients for actionable molecular biomarkers to guide treatment.

Patients will be eligible for treatment in substudies based on the expression of actionable mutations or other molecular biomarkers in their tumours. For some treatments, where predictive biomarkers are not well characterised or thresholds are unknown, a post-hoc analysis will be performed to identify biomarkers.
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Sample size
A minimum of 1000 patients will be recruited for screening to identify actionable mutations and eligibility for enrolment into MoST substudies.

This protocol provides a framework to conduct molecular screening of patients and the development and implementation of multiple, parallel, early-phase, signal-seeking substudy trials. It is planned that 12 substudy modules will be opened during the first 4 years of the study. Each substudy will enrol 16 patients. A primarily descriptive analysis will be used to evaluate the feasibility, efficiency, utility and costs of the framework protocol, with data about the development and conduct of each substudy contributing to this analysis. Data about unsuccessful substudies (ie trial concepts that do not progress to a substudy within the MoST program) will also be collected to inform the evaluation of the framework.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
9/09/2016
Actual
30/08/2016
Date of last participant enrolment
Anticipated
31/12/2024
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
7628
Accrual to date
7279
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC
Recruitment hospital [1] 5755 0
St Vincent's Hospital (Darlinghurst) - Darlinghurst
Recruitment hospital [2] 5756 0
The Chris O’Brien Lifehouse - Camperdown
Recruitment hospital [3] 10340 0
St George Hospital - Kogarah
Recruitment hospital [4] 13167 0
Linear Clinical Research - Nedlands
Recruitment hospital [5] 13168 0
The Canberra Hospital - Garran
Recruitment hospital [6] 26407 0
The Royal Adelaide Hospital - Adelaide
Recruitment hospital [7] 26408 0
Royal Hobart Hospital - Hobart
Recruitment hospital [8] 26409 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [9] 26410 0
Royal Darwin Hospital - Tiwi
Recruitment hospital [10] 26411 0
Royal Brisbane & Womens Hospital - Herston
Recruitment postcode(s) [1] 13225 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 13226 0
2050 - Camperdown
Recruitment postcode(s) [3] 22011 0
2217 - Kogarah
Recruitment postcode(s) [4] 25722 0
6009 - Nedlands
Recruitment postcode(s) [5] 25723 0
2605 - Garran
Recruitment postcode(s) [6] 42383 0
5000 - Adelaide
Recruitment postcode(s) [7] 42384 0
7000 - Hobart
Recruitment postcode(s) [8] 42385 0
4102 - Woolloongabba
Recruitment postcode(s) [9] 42386 0
0810 - Tiwi
Recruitment postcode(s) [10] 42387 0
3004 - Melbourne
Recruitment postcode(s) [11] 42388 0
4029 - Herston

Funding & Sponsors
Funding source category [1] 293552 0
Government body
Name [1] 293552 0
Office for Health and Medical Research
Country [1] 293552 0
Australia
Funding source category [2] 303595 0
Other Collaborative groups
Name [2] 303595 0
Australian Genomic Cancer Medicine Centre
Country [2] 303595 0
Australia
Primary sponsor type
University
Name
University of Sydney
Address
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450
Country
Australia
Secondary sponsor category [1] 292366 0
None
Name [1] 292366 0
Address [1] 292366 0
Country [1] 292366 0
Other collaborator category [1] 280912 0
Other Collaborative groups
Name [1] 280912 0
Australian Genomic Cancer Medicine Centre
Address [1] 280912 0
Kinghorn Cancer Centre,
370 Victoria Street,
Darlinghurst NSW 2010
Country [1] 280912 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 294991 0
St Vincent's Hospital Sydney Human Research Ethics Committee
Ethics committee address [1] 294991 0
390 Victoria Street
Darlinghurst NSW 2010
Ethics committee country [1] 294991 0
Australia
Date submitted for ethics approval [1] 294991 0
01/02/2016
Approval date [1] 294991 0
01/04/2016
Ethics approval number [1] 294991 0
HREC/16/SVH/23

Summary
Brief summary
This study aims to screen patients with advanced cancer and unmet clinical needs for actionable biomarkers to be used to guide therapy.
Who is it for? You may be eligible to join this study if you are aged 18 years and older, with pathologically confirmed advanced and/or metastatic solid cancer of any cell type or an earlier diagnosis of a poor prognosis cancer and have received all standard anticancer therapy.
Study details: A small part of your tumour tissue, which was collected from a previous biopsy or surgery, will be used to identify a biomarker by doing a laboratory analysis (‘molecular screening’). The screening includes genetic panel testing, which means looking for changes in a subset of genes (DNA) in your tumour tissue and other laboratory assays. You will be asked to provide information about your and your family’s health background, to donate a blood sample and complete some questionnaires.
Results from molecular screening will be returned to all participants. These results may have implications for your treatment if a suitable biomarker is found.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 65698 0
Prof David Thomas
Address 65698 0
Garvan Institute of Medical Research
The Kinghorn Cancer Centre, 370 Victoria Street
Darlinghurst NSW 2010
Country 65698 0
Australia
Phone 65698 0
+612 9355 5770
Fax 65698 0
+612 9355 5872
Email 65698 0
[email protected]
Contact person for public queries
Name 65699 0
Sarah Finlayson
Address 65699 0
NHMRC Clinical Trials Centre
Level 6, Chris O'Brien Lifehouse
119–143 Missenden Road, Camperdown NSW 2050
Country 65699 0
Australia
Phone 65699 0
+61295625000
Fax 65699 0
Email 65699 0
[email protected]
Contact person for scientific queries
Name 65700 0
David Thomas
Address 65700 0
Garvan Institute of Medical Research
The Kinghorn Cancer Centre, 370 Victoria Street
Darlinghurst NSW 2010
Country 65700 0
Australia
Phone 65700 0
+612 9355 5770
Fax 65700 0
+612 9355 5872
Email 65700 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Currently no plan and participant consent will be required


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AIThe PiGeOn project: protocol for a longitudinal study examining psychosocial, behavioural and ethical issues and outcomes in cancer tumour genomic profiling2018https://doi.org/10.1186/s12885-018-4310-0
EmbaseThe Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review.2020https://dx.doi.org/10.1016/j.clinthera.2020.05.010
EmbaseComprehensive histopathologic and genomic analysis of a novel case of lipoblastoma-like tumour of the vulva demonstrating malignant behaviour.2022https://dx.doi.org/10.1016/j.hpr.2022.300678
EmbaseMolecular therapy selection in treatment-refractory advanced cancers: A retrospective cohort study determining the utility of TOPOGRAPH knowledge base.2022https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.3073
Dimensions AITopological barrier to Cas12a activation by circular DNA nanostructures facilitates autocatalysis and transforms DNA/RNA sensing2024https://doi.org/10.1038/s41467-024-46001-8
N.B. These documents automatically identified may not have been verified by the study sponsor.